Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer

Yilv Yan^#¹, Dongqing Sun^#^{2

3}, Junjie Hu^#¹, Yue Chen^#⁴, Liangdong Sun¹, Huansha Yu¹, Yicheng Xiong¹, Zhida Huang¹, Haoran Xia¹, Xinsheng Zhu¹, Dongliang Bian¹, Fenghuan Sun¹, Likun Hou⁵, Chunyan Wu⁵, Orion R Fan⁶, Haiyang Hu⁷, An Zeng⁸, Lele Zhang⁹, Yi Eve Sun¹⁰, Chenfei Wang^{11

12

13

14}, Peng Zhang^{15

16}

Affiliations

¹ Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
² Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Orthopedics, Tongji Hospital, School of Life Science and Technology, Tongji University, Shanghai, China.
³ Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.
⁴ State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
⁵ Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
⁶ Stem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
⁷ Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
⁸ State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China. azeng@sibcb.ac.cn.
⁹ Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. zhanglele@tongji.edu.cn.
¹⁰ Stem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. yi.eve.sun@gmail.com.
¹¹ Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Orthopedics, Tongji Hospital, School of Life Science and Technology, Tongji University, Shanghai, China. 08chenfeiwang@tongji.edu.cn.
¹² Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China. 08chenfeiwang@tongji.edu.cn.
¹³ National Key Laboratory of Autonomous Intelligent Unmanned Systems, Tongji University, Shanghai, China. 08chenfeiwang@tongji.edu.cn.
¹⁴ Frontier Science Center for Intelligent Autonomous Systems, Tongji University, Shanghai, China. 08chenfeiwang@tongji.edu.cn.
¹⁵ Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. zhangpeng1121@tongji.edu.cn.
¹⁶ Department of Thoracic Surgery, The First Affiliated Hospital of Shihezi University Medical College, Shihezi, China. zhangpeng1121@tongji.edu.cn.

^# Contributed equally.

PMID: 39658657
DOI: 10.1038/s41588-024-01998-y

Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer

Yilv Yan et al. Nat Genet. 2025 Jan.

. 2025 Jan;57(1):126-139.

doi: 10.1038/s41588-024-01998-y. Epub 2024 Dec 10.

Authors

Affiliations

¹ Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
² Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Orthopedics, Tongji Hospital, School of Life Science and Technology, Tongji University, Shanghai, China.
³ Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.
⁴ State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
⁵ Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
⁶ Stem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
⁷ Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
⁸ State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China. azeng@sibcb.ac.cn.
⁹ Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. zhanglele@tongji.edu.cn.
¹⁰ Stem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. yi.eve.sun@gmail.com.
¹¹ Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Orthopedics, Tongji Hospital, School of Life Science and Technology, Tongji University, Shanghai, China. 08chenfeiwang@tongji.edu.cn.
¹² Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China. 08chenfeiwang@tongji.edu.cn.
¹³ National Key Laboratory of Autonomous Intelligent Unmanned Systems, Tongji University, Shanghai, China. 08chenfeiwang@tongji.edu.cn.
¹⁴ Frontier Science Center for Intelligent Autonomous Systems, Tongji University, Shanghai, China. 08chenfeiwang@tongji.edu.cn.
¹⁵ Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. zhangpeng1121@tongji.edu.cn.
¹⁶ Department of Thoracic Surgery, The First Affiliated Hospital of Shihezi University Medical College, Shihezi, China. zhangpeng1121@tongji.edu.cn.

^# Contributed equally.

PMID: 39658657
DOI: 10.1038/s41588-024-01998-y

Abstract

Although immune checkpoint blockade (ICB) therapies have shifted the treatment paradigm for non-small-cell lung cancer (NSCLC), many patients remain resistant. Here we characterize the tumor cell states and spatial cellular compositions of the NSCLC tumor microenvironment (TME) by analyzing single-cell transcriptomes of 232,080 cells and spatially resolved transcriptomes of tumors from 19 patients before and after ICB-chemotherapy. We find that tumor cells and secreted phosphoprotein 1-positive macrophages interact with collagen type XI alpha 1 chain-positive cancer-associated fibroblasts to stimulate the deposition and entanglement of collagen fibers at tumor boundaries, obstructing T cell infiltration and leading to poor prognosis. We also reveal distinct states of tertiary lymphoid structures (TLSs) in the TME. Activated TLSs are associated with improved prognosis, whereas a hypoxic microenvironment appears to suppress TLS development and is associated with poor prognosis. Our study provides novel insights into different cellular and molecular components corresponding to NSCLC ICB-chemotherapeutic responsiveness, which will benefit future individualized immuno-chemotherapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

References

1. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015). - PubMed - PMC
1. Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018). - PubMed
1. Bian, D. L. et al. Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study. Nat. Commun. 14, 4655 (2023). - PubMed - PMC
1. Lu, S. et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch Randomized Clinical Trial. J. Am. Med. Assoc. 331, 201–211 (2024).
1. Xia, H. R. et al. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study. Signal Transduct. Target. Ther. 9, 145 (2024). - PubMed - PMC

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer

Affiliations

Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer

Authors

Affiliations

Abstract

Conflict of interest statement

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials